The Princess Alexandra Hospital is a major Australian teaching hospital of the University of Queensland, located in Brisbane, Queensland. It is a tertiary level teaching hospital with all major medical and surgical specialities onsite except for obstetrics, gynaecology and paediatrics.

There are 1,038 beds in Princess Alexandra Hospital.

During the past decade, Princess Alexandra Hospital conducted 272 clinical trials. In the 10-year time frame, 272 clinical trials started and 103 clinical trials were completed, i.e. on average, 37.9% percent of trials that started reached the finish line to date. In the past 5 years, 93 clinical trials started and 59 clinical trials were completed. i.e. 63.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Princess Alexandra Hospital" #1 sponsor was "Hoffmann-La Roche" with 45 trials, followed by "Trans Tasman Radiation Oncology Group" with 23 trials sponsored, "Celgene" with 20 trials sponsored, "Janssen Research & Development, LLC" with 14 trials sponsored and "The University of Queensland" with 14 trials sponsored. Other sponsors include 333 different institutions and companies that sponsored additional 183 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Princess Alexandra Hospital" #1 collaborator was "National Health and Medical Research Council, Australia" with 23 trials as a collaborator, "AstraZeneca" with 8 trials as a collaborator, "Princess Alexandra Hospital, Brisbane, Australia" with 8 trials as a collaborator, "Trans Tasman Radiation Oncology Group" with 8 trials as a collaborator and "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 7 trials as a collaborator. Other collaborators include 389 different institutions and companies that were collaborators in the rest 266 trials.

According to Clinical.Site data, the most researched conditions in "Princess Alexandra Hospital" are "Melanoma" (18 trials), "Breast Cancer" (14 trials), "Ulcerative Colitis" (13 trials), "Prostate Cancer" (12 trials) and "Multiple Myeloma" (10 trials). Many other conditions were trialed in "Princess Alexandra Hospital" in a lesser frequency.

Most popular intervention types in "Princess Alexandra Hospital" are "Drug" (353 trials), "Other" (59 trials), "Radiation" (41 trials), "Device" (28 trials) and "Biological" (27 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (95 trials), "Rituximab" (16 trials), "Atezolizumab" (14 trials), "Cyclophosphamide" (10 trials) and "Paclitaxel" (10 trials). Other intervention names were less common.

The vast majority of trials in "Princess Alexandra Hospital" are 427 trials for "All" genders, 20 trials for "Male" genders and 6 trials for "Female" genders.

Currently, there are 198 active trials in "Princess Alexandra Hospital". 6 are not yet recruiting, 100 are recruiting, 86 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 189 completed trials in Princess Alexandra Hospital, 1 suspended trials, and 37 terminated clinical trials to date.

Out of the total trials that were conducted in Princess Alexandra Hospital, 38 "Phase 1" clinical trials were conducted, 124 "Phase 2" clinical trials and 241 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 14 trials, and there were also 49 trials that are defined as “Not Applicable".